RT Journal Article
SR Electronic
T1 Delivery of CPAP respiratory support for COVID-19 using repurposed technologies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.06.20055665
DO 10.1101/2020.04.06.20055665
A1 Culmer, P.
A1 Keeling, A.
A1 Osnes, C.
A1 Birch, W. Davis
A1 Jones, D.
A1 Waters, I.
A1 Hetherington, R.
A1 Parmar, J.
A1 Lawton, T.
A1 Ashton, S.
A1 Latham, M.
A1 Murdoch, S.
A1 Brettle, D.
A1 Kapur, N.
YR 2020
UL http://medrxiv.org/content/early/2020/04/19/2020.04.06.20055665.abstract
AB The COVID-19 pandemic has placed a dramatic increase in demand on healthcare providers to provide respiratory support for patients with moderate to severe symptoms. In conjunction, the pandemic has challenged existing supply-chains to meet demands for medical equipment and resources. In response to these challenges, we report our work to repurpose two existing non-invasive ventilation (NIV) systems to provide solutions for the delivery of oxygen-enriched CPAP ventilation which are inherently resource and oxygen-efficient. We consider adaptation of CPAP systems typically used for sleep apnoea, together with a new Venturi-valve design which can be readily produced through 3D printing. Our aim in both cases was to support Positive end-expiratory pressure (PEEP) of ≥10cmH2O while achieving ≥40% FiO2. This supports a crucial part in the patient pathway for COVID-19 treatment, helping to provide early respiratory support prior to invasive ventilation options in the ICU.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research is supported by the National Institute for Health Research (NIHR) infrastructure at Leeds. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The authors would like to thank the NIHR MedTech and In Vitro diagnostics Co-operatives (MICs). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther data is available from the research team on request.